Loading...
•
Jun 30, 2024
AbbVie Q2 2024 Earnings Report
AbbVie's financial performance significantly exceeded expectations, driven by the strong momentum of its ex-Humira growth platform and strategic investments.
Key Takeaways
AbbVie reported a strong second quarter with net revenues of $14.462 billion, a 4.3% increase, and a GAAP EPS of $0.77. The company is raising its full-year adjusted diluted EPS guidance to $10.71 - $10.91.
Net revenues reached $14.462 billion, a 4.3% increase on a reported basis.
Global net revenues from the Immunology portfolio were $6.971 billion, up by 2.3%.
Global net revenues from the Oncology portfolio increased by 10.5% to $1.634 billion.
Adjusted diluted EPS was $2.65, which includes an unfavorable impact of $0.52 per share related to acquired IPR&D and milestones expense.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 - $10.81 to $10.71 - $10.91, which includes an unfavorable impact of $0.60 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...